Fennec Pharmaceuticals Inc (FENC) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Fennec Pharmaceuticals Inc   (NASDAQ: FENC)

Select the Financial Report: Select the Period:


Description of Fennec Pharmaceuticals Inc's Business Segments


The Company operates and manages its business within a single operating segment focused on the production and commercialization of PEDMARK. All employees support this segment exclusively.


(Mar 31 2026) three months ended Q1
Business Segments Revenues
(in millions $)
Income
(in millions $)
%
(Profit Margin)
Total 15.11 0.20 1.33 %

(Mar 31 2026) three months ended Q1
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Total 72.64 % 9.66 %

(Mar 31 2026) three months ended Q1
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Total - -


Annual Report on Fennec Pharmaceuticals Inc Divisions, Sales by Country

 


Twelve months ended 2025
FENC s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Total 44.64 100 %


Twelve months ended 2025
FENC s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total -9.74 -

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Total -6.09 % -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.